TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates

TG Therapeutics (TGTX) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of$ 0.04 per share. This compares to loss of $0.34 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 200%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.03 per share when it actually produced a loss of $0.07, delivering a surprise of -133.33%. Over the last four ...